Elicio Therapeutics announced three confirmed complete responses in metastatic KRAS-mutant pancreatic cancer patients who progressed after ELI-002 7P treatment and then received nivolumab-based checkpoint inhibitor therapy. These complete responses, which are rare in this cancer type, suggest that ELI-002 7P may enhance immune sensitivity to checkpoint inhibitors. Elicio plans to start a Phase 1 study combining ELI-002 7P with checkpoint inhibition in metastatic pancreatic cancer, aiming for rapid clinical assessment and informing future Phase 3 trials. The findings support the potential of ELI-002 7P to improve treatment outcomes in a cancer type traditionally resistant to immunotherapy.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Viasat and BMW Group have successfully demonstrated the first integrated automotive satellite voice call, allowing drivers to make calls directly through the car's infotainment system even in areas without cellular coverage. This advancement, utilizi...
Iran has warned it will retaliate fiercely if the US targets its infrastructure, following President Trump's threat to strike Iranian power plants and bridges next week if negotiations fail. The US recently conducted airstrikes against Iranian milita...
Solana (SOL) maintains its price in the mid-$70 range, supported by several key developments. These include Circle's recent issuance of $500 million in USDC on the Solana network, increasing liquidity and transactional demand. Additionally, instituti...
